 <h1>Eylea Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>aflibercept ophthalmic</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about aflibercept ophthalmic. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Eylea.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> increased intraocular pressure.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to aflibercept ophthalmic: intraocular solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, aflibercept ophthalmic (the active ingredient contained in Eylea) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking aflibercept ophthalmic:</p><p>
<i>More common</i>
</p><ul>
<li>Blindness</li>
<li>bloody eye</li>
<li>blurred vision</li>
<li>eye or eyelid redness</li>
<li>eye pain</li>
<li>seeing flashes, sparks of light, or a veil or curtain</li>
<li>seeing floating spots before the eyes</li>
<li>vision changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding or pain at the injection site</li>
<li>swelling of the eyelid</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, rash, or skin redness</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>swelling of the eye, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Pain in the chest, groin, or legs, especially the calves</li>
<li>severe, sudden headache</li>
<li>slurred speech</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of aflibercept ophthalmic may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Feeling like something is in the eye</li>
<li>watery eyes</li>
</ul><p>
<!-- end intraocular solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aflibercept ophthalmic: intravitreal solution</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctival hemorrhage (28%), eye pain (13%), </p>
<p><b>Common</b> (1% to 10%): Cataract, vitreous floaters, corneal erosion, intraocular pressure increased, conjunctival hyperemia, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increased, vision blurred, intraocular inflammation, retinal pigment epithelium tear, injection site hemorrhage, eyelid edema, corneal edema, retinal degeneration, cataract, cataract nuclear, cataract subcapsular, corneal abrasion, intraocular pressure increased, vitreous floaters</p>
<p><b>Uncommon</b> (0.1% to 1%): Retinal detachment, retinal tear, endophthalmitis injection site pain, traumatic cataract<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Intravitreal use of VEGF inhibitors has been associated with a potential risk of arterial thromboembolic events (ATEs) defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including death of unknown cause).  In wet age-related macular degeneration (AMD) studies, 1.8% (n=32/1824) and 1.5% (n=9/595) of patients treated with this drug or ranibizumab, respectively, experienced an ATE in the first 52 weeks and 3.3% and 3.2% through 96 weeks, respectively.  In the diabetic macular edema (DME) studies, ATEs were reported at incidences of 3.3% (n=19/578) and 2.8% (n=8/287) through week 52, and 6.4% (n=37/578) and 4.2% (n=12/287) through week 100, in patients receiving 2 different dosing regimens of this drug or macular laser photocoagulation (after the first 24 weeks, all patients could receive drug or laser treatment).  No ATEs have been reported in the first 6 months of the retinal vein occlusion (RVO) studies.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Arterial thromboembolic events<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Eylea (aflibercept ophthalmic)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>30 Reviews</li>
<li>Drug class: anti-angiogenic ophthalmic agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Eylea &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Macular Edema</li>
<li>Macular Degeneration</li>
<li>Diabetic Macular Edema</li>
<li>Diabetic Retinopathy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aflibercept ophthalmic: intravitreal solution</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctival hemorrhage (28%), eye pain (13%), </p><p><b>Common</b> (1% to 10%): Cataract, vitreous floaters, corneal erosion, intraocular pressure increased, conjunctival hyperemia, ocular hyperemia, vitreous detachment, foreign body sensation in eyes, lacrimation increased, vision blurred, intraocular inflammation, retinal pigment epithelium tear, injection site hemorrhage, eyelid edema, corneal edema, retinal degeneration, cataract, cataract nuclear, cataract subcapsular, corneal abrasion, intraocular pressure increased, vitreous floaters</p><p><b>Uncommon</b> (0.1% to 1%): Retinal detachment, retinal tear, endophthalmitis injection site pain, traumatic cataract<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Intravitreal use of VEGF inhibitors has been associated with a potential risk of arterial thromboembolic events (ATEs) defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including death of unknown cause).  In wet age-related macular degeneration (AMD) studies, 1.8% (n=32/1824) and 1.5% (n=9/595) of patients treated with this drug or ranibizumab, respectively, experienced an ATE in the first 52 weeks and 3.3% and 3.2% through 96 weeks, respectively.  In the diabetic macular edema (DME) studies, ATEs were reported at incidences of 3.3% (n=19/578) and 2.8% (n=8/287) through week 52, and 6.4% (n=37/578) and 4.2% (n=12/287) through week 100, in patients receiving 2 different dosing regimens of this drug or macular laser photocoagulation (after the first 24 weeks, all patients could receive drug or laser treatment).  No ATEs have been reported in the first 6 months of the retinal vein occlusion (RVO) studies.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Arterial thromboembolic events<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc, Tarrytown, NY. </p><h2>More about Eylea (aflibercept ophthalmic)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>30 Reviews</li>
<li>Drug class: anti-angiogenic ophthalmic agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Eylea &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Macular Edema</li>
<li>Macular Degeneration</li>
<li>Diabetic Macular Edema</li>
<li>Diabetic Retinopathy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>